Trius Therapeutics Initiates Phase 3 Program of Oral Torezolid Phosphate for the Treatment of ABSSSI
Trius Therapeutics Reports 2010 Second Quarter Results
Trius Therapeutics Announces Pricing For Initial Public Offering
Publication: Comparative Activity of TR-700 (Torezolid) Against Staphylococcal Blood Isolates..., Betrui et al.
Publication: Comparative in vitro Antimicrobial Activity of Torezolid (TR-700)...,Brown et al.
Trius Therapeutics Presents New Data Featuring Torezolid Antibiotic at the 20th ECCMID Meeting.